Compugen Ltd (CGEN) 7.13 $CGEN
Should Compugen (CGEN) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:35AM CST
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Compugen, the stock of which company has actually seen rising estimates over the past one month.
CGEN: 7.13 (+0.02)
Compugen incurs higher net loss of USD5.4m for Q3 2014
M2 - Thu Oct 30, 6:13AM CDT
Drug discovery company Compugen (NASDAQ:CGEN) stated on Wednesday its net loss of USD5.4m (USD0.11 per diluted share) for the third quarter ending 30 September 2014.
CGEN: 7.13 (+0.02)
Compugen posts 3Q loss
Automated Insights - Wed Oct 29, 9:07AM CDT
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Wednesday reported a loss of $5.4 million, or 11 cents per share, in its third quarter.
CGEN: 7.13 (+0.02)
Compugen Ltd. Reports Third Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 6:13AM CDT
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the third quarter and nine months ending September 30, 2014.
CGEN: 7.13 (+0.02)
Compugen Discloses Successful Validation Results for Novel B7/CD28-like Cancer Immunotherapy Target Candidate
Business Wire - Mon Oct 27, 6:01AM CDT
--Compugen-discovered immune checkpoint candidates show potential for development of multiple cancer immunotherapies
CGEN: 7.13 (+0.02)
Compugen Third Quarter 2014 Conference Call Scheduled for Wednesday, October 29, 2014 at 10:00 AM ET
Business Wire - Wed Oct 22, 6:11AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM ET on Wednesday, October 29, 2014 to review third quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call.
CGEN: 7.13 (+0.02)
Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 59.34 (+0.08), CGEN: 7.13 (+0.02), TEVA: 57.70 (-1.02), AMPE: 3.82 (+0.12), MNTA: 10.98 (+0.10), NVS: 91.76 (-0.27)
RTM Consulting to Present 'Consulting Soft Skills: Mission Critical for B4B Suppliers' at Technology Services World
Marketwired - Wed Oct 15, 9:11AM CDT
Cincinnati-based RTM Consulting, the leading provider of Resource Management solutions for consulting, professional and support services organizations in the IT sector, today announced they will co-present with the Technology Services Industry Association (TSIA) and RTM Consulting clients Compugen, Medidata Solutions and Ontario Systems at Technology Services World 2014 Service Transformations conference, taking place October 20 - 22 at the ARIA Resort in Las Vegas. The Technology Services World conference has become renowned as the preeminent source of learning and peer networking for technology services professionals.
MDSO: 43.84 (+0.36), CGEN: 7.13 (+0.02)
Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer
Business Wire - Tue Oct 14, 1:02PM CDT
Compugen Ltd. (NASDAQ: CGEN) disclosed today that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced today relates to the second preclinical milestone for one of the checkpoint protein candidates. The achievement of the initial milestone for this candidate was announced in July of this year.
CGEN: 7.13 (+0.02)
Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences
Business Wire - Mon Oct 06, 6:08AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that certain aspects of its predictive approach to therapeutics discovery as applied to novel immune checkpoints will be presented in poster sessions at three leading scientific conferences this month and next. The presentations also include experimental results from some of the immune checkpoint based product candidate programs addressing cancer immunotherapy and autoimmune diseases now being pursued by the Company:
CGEN: 7.13 (+0.02)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ACE: 110.81 (+0.08), COF: 82.60 (+0.52), CBK: 6.70 (-0.04), CGEN: 7.13 (+0.02), BPFH: 13.17 (-0.02)
Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy
Business Wire - Wed Oct 01, 6:01AM CDT
--CGEN-15049 therapeutic antibody development is underway
CGEN: 7.13 (+0.02)
Compugen Announces Presentations of Results for CGEN-15001 Supporting Immune Tolerance Induction
Business Wire - Mon Sep 29, 6:04AM CDT
Compugen Ltd. (NASDAQ: CGEN) announced today that experimental results supporting CGEN-15001's induction of long-term autoimmune disease remission in disease animal models, potentially through a novel mechanism of action, are being presented at two sessions at the 3rd International Conference on Immune Tolerance, now being held in Amsterdam, the Netherlands, from September 28-30, 2014. The presentations are being given by Joseph R. Podojil, PhD, of Northwestern University Feinberg School of Medicine, and by Iris Hecht, PhD, Principal Scientist at Compugen.
CGEN: 7.13 (+0.02)
Compugen Signs Multi-Year Contract With FortisBC
Marketwire Canada - Tue Sep 23, 11:00AM CDT
Compugen Inc. is pleased to announce that it has signed a multi-year contract to supply FortisBC with IT Customer and Infrastructure Services starting January 2015. This contract will see Compugen's Managed Services division take responsibility for all of the IT Operations, ITSM Processes and Tools, including the support of 2,500 employees and contractors involved in the company's natural gas operations in over 65 locations across British Columbia.
CGEN: 7.13 (+0.02)
Global Bone Marrow Transplantation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxqmms/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - melphalan - Allogeneic MPC for Bone Marrow Transplantation - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Central Memory T Cell Therapy for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/fx...one_marrow
PSTI: 2.66 (-0.08), CGEN: 7.13 (+0.02), SPPI: 7.33 (-0.15), CBLI: 0.44 (+0.02)
Can The Uptrend Continue for Compugen (CGEN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:32AM CDT
Can The Uptrend Continue for Compugen (CGEN)?
CGEN: 7.13 (+0.02)
Compugen Honoured as a Winner of Microsoft's Excellence in Operations -- Gold Level Award
Marketwire Canada - Thu Sep 04, 11:00AM CDT
Today Compugen announced it has won the Gold Level Excellence in Operations Award for delivering market-leading operational excellence supporting Microsoft technology over the past year.
CGEN: 7.13 (+0.02)
Compugen (CGEN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:39AM CDT
Compugen is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
CGEN: 7.13 (+0.02)
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
A: 40.93 (-0.44), OSIR: 13.50 (-0.34), ILMN: 186.35 (-3.52), LMNX: 18.04 (-0.75), AFFX: 9.43 (-0.02), QGEN: 23.48 (-0.20), BCOR: 14.79 (-0.21), ACCL: 12.51 (+0.03), ABT: 43.37 (-0.32), INCY: 69.32 (+0.92), BMY: 58.32 (-0.14), WAT: 111.05 (-1.83), ISIS: 44.59 (-0.66), SIAL: 135.34 (unch), BASI: 2.35 (-0.16), MRK: 59.34 (+0.08), CGEN: 7.13 (+0.02), CRL: 63.36 (-0.37), CELGZ: 3.24 (-0.04), NVS: 91.76 (-0.27)
Compugen Has Returned 14.7% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu Aug 28, 4:59PM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 5 months, Compugen has returned 14.71% as of today's recent price of $8.84.
CGEN: 7.13 (+0.02)
Should Compugen (CGEN) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:35AM CST
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Compugen, the stock of which company has actually seen rising estimates over the past one month.
CGEN: 7.13 (+0.02)
Compugen incurs higher net loss of USD5.4m for Q3 2014
M2 - Thu Oct 30, 6:13AM CDT
Drug discovery company Compugen (NASDAQ:CGEN) stated on Wednesday its net loss of USD5.4m (USD0.11 per diluted share) for the third quarter ending 30 September 2014.
CGEN: 7.13 (+0.02)
Compugen posts 3Q loss
Automated Insights - Wed Oct 29, 9:07AM CDT
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Wednesday reported a loss of $5.4 million, or 11 cents per share, in its third quarter.
CGEN: 7.13 (+0.02)
Compugen Ltd. Reports Third Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 6:13AM CDT
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the third quarter and nine months ending September 30, 2014.
CGEN: 7.13 (+0.02)
Compugen Discloses Successful Validation Results for Novel B7/CD28-like Cancer Immunotherapy Target Candidate
Business Wire - Mon Oct 27, 6:01AM CDT
--Compugen-discovered immune checkpoint candidates show potential for development of multiple cancer immunotherapies
CGEN: 7.13 (+0.02)
Compugen Third Quarter 2014 Conference Call Scheduled for Wednesday, October 29, 2014 at 10:00 AM ET
Business Wire - Wed Oct 22, 6:11AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM ET on Wednesday, October 29, 2014 to review third quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call.
CGEN: 7.13 (+0.02)
Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 59.34 (+0.08), CGEN: 7.13 (+0.02), TEVA: 57.70 (-1.02), AMPE: 3.82 (+0.12), MNTA: 10.98 (+0.10), NVS: 91.76 (-0.27)
RTM Consulting to Present 'Consulting Soft Skills: Mission Critical for B4B Suppliers' at Technology Services World
Marketwired - Wed Oct 15, 9:11AM CDT
Cincinnati-based RTM Consulting, the leading provider of Resource Management solutions for consulting, professional and support services organizations in the IT sector, today announced they will co-present with the Technology Services Industry Association (TSIA) and RTM Consulting clients Compugen, Medidata Solutions and Ontario Systems at Technology Services World 2014 Service Transformations conference, taking place October 20 - 22 at the ARIA Resort in Las Vegas. The Technology Services World conference has become renowned as the preeminent source of learning and peer networking for technology services professionals.
MDSO: 43.84 (+0.36), CGEN: 7.13 (+0.02)
Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer
Business Wire - Tue Oct 14, 1:02PM CDT
Compugen Ltd. (NASDAQ: CGEN) disclosed today that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced today relates to the second preclinical milestone for one of the checkpoint protein candidates. The achievement of the initial milestone for this candidate was announced in July of this year.
CGEN: 7.13 (+0.02)
Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences
Business Wire - Mon Oct 06, 6:08AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that certain aspects of its predictive approach to therapeutics discovery as applied to novel immune checkpoints will be presented in poster sessions at three leading scientific conferences this month and next. The presentations also include experimental results from some of the immune checkpoint based product candidate programs addressing cancer immunotherapy and autoimmune diseases now being pursued by the Company:
CGEN: 7.13 (+0.02)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ACE: 110.81 (+0.08), COF: 82.60 (+0.52), CBK: 6.70 (-0.04), CGEN: 7.13 (+0.02), BPFH: 13.17 (-0.02)
Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy
Business Wire - Wed Oct 01, 6:01AM CDT
--CGEN-15049 therapeutic antibody development is underway
CGEN: 7.13 (+0.02)
Compugen Announces Presentations of Results for CGEN-15001 Supporting Immune Tolerance Induction
Business Wire - Mon Sep 29, 6:04AM CDT
Compugen Ltd. (NASDAQ: CGEN) announced today that experimental results supporting CGEN-15001's induction of long-term autoimmune disease remission in disease animal models, potentially through a novel mechanism of action, are being presented at two sessions at the 3rd International Conference on Immune Tolerance, now being held in Amsterdam, the Netherlands, from September 28-30, 2014. The presentations are being given by Joseph R. Podojil, PhD, of Northwestern University Feinberg School of Medicine, and by Iris Hecht, PhD, Principal Scientist at Compugen.
CGEN: 7.13 (+0.02)
Compugen Signs Multi-Year Contract With FortisBC
Marketwire Canada - Tue Sep 23, 11:00AM CDT
Compugen Inc. is pleased to announce that it has signed a multi-year contract to supply FortisBC with IT Customer and Infrastructure Services starting January 2015. This contract will see Compugen's Managed Services division take responsibility for all of the IT Operations, ITSM Processes and Tools, including the support of 2,500 employees and contractors involved in the company's natural gas operations in over 65 locations across British Columbia.
CGEN: 7.13 (+0.02)
Global Bone Marrow Transplantation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxqmms/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - melphalan - Allogeneic MPC for Bone Marrow Transplantation - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Central Memory T Cell Therapy for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/fx...one_marrow
PSTI: 2.66 (-0.08), CGEN: 7.13 (+0.02), SPPI: 7.33 (-0.15), CBLI: 0.44 (+0.02)
Can The Uptrend Continue for Compugen (CGEN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:32AM CDT
Can The Uptrend Continue for Compugen (CGEN)?
CGEN: 7.13 (+0.02)
Compugen Honoured as a Winner of Microsoft's Excellence in Operations -- Gold Level Award
Marketwire Canada - Thu Sep 04, 11:00AM CDT
Today Compugen announced it has won the Gold Level Excellence in Operations Award for delivering market-leading operational excellence supporting Microsoft technology over the past year.
CGEN: 7.13 (+0.02)
Compugen (CGEN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:39AM CDT
Compugen is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
CGEN: 7.13 (+0.02)
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery A: 40.93 (-0.44), OSIR: 13.50 (-0.34), ILMN: 186.35 (-3.52), LMNX: 18.04 (-0.75), AFFX: 9.43 (-0.02), QGEN: 23.48 (-0.20), BCOR: 14.79 (-0.21), ACCL: 12.51 (+0.03), ABT: 43.37 (-0.32), INCY: 69.32 (+0.92), BMY: 58.32 (-0.14), WAT: 111.05 (-1.83), ISIS: 44.59 (-0.66), SIAL: 135.34 (unch), BASI: 2.35 (-0.16), MRK: 59.34 (+0.08), CGEN: 7.13 (+0.02), CRL: 63.36 (-0.37), CELGZ: 3.24 (-0.04), NVS: 91.76 (-0.27)
Compugen Has Returned 14.7% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu Aug 28, 4:59PM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 5 months, Compugen has returned 14.71% as of today's recent price of $8.84.
CGEN: 7.13 (+0.02)
